Centro Pesquisas Oncologicas - CEPON

Centro Pesquisas Oncologicas - CEPON
655 Rio Itacorubi Florianópolis SC BR 88034-000, Rod. Admar Gonzaga - Itacorubi, Florianópolis - SC
Select an option

Our team

Medical staff
Fabricio Pontes
Camila Donadel
Camila Sommer
Hanaludia Machado
Anne Schmitz
Rita Ferrua de Oliveira

Open studies

Gastroesophageal cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer - Destiny-Gastric05 - Daiichi SankyoSee more
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer - Destiny-Gastric05 - Daiichi SankyoSee more
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Cervical cancer
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer - Nivolumab - Hospital Israelita Albert EinsteinSee more
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Breast Cancer
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer - DESTINY-Breast15 - Daiichi SankyoSee more
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Gastric cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer - Destiny-Gastric05 - Daiichi SankyoSee more
Solid tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Endometrial Cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Head and neck cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Colorectal cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Liver Cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Esophageal cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Gastrointestinal Cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Ovarian cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Urologic cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Bile Duct Cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Skin cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Pancreatic cancer
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy